EBV-Mir-BART5-5p targets p53 independent pathway in cytoplasm: Potential role in EBV lymphomagenesis

• Wei-Ting Wang,
• Jing-Ran Guo,
• Li Wang,
• Jia-Zhu Wu,
• Hao-Rui Shen,
• Yi-Lin Kong,
• Yi Xia,
• Jian-Yong Li,
• Jin-Hua Liang,
• Wei Xu

Affiliations

Wei-Ting Wang

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China

Jing-Ran Guo

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China

Li Wang

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China

Jia-Zhu Wu

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China

Hao-Rui Shen

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China

Yi-Lin Kong

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China

Yi Xia

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China

Jian-Yong Li

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China

Jin-Hua Liang

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China; Corresponding author. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China.

Wei Xu

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China; Key Laboratory of Hematology of Nanjing Medical University, Nanjing, Jiangsu 210029, China; Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, Jiangsu 210029, China; Corresponding author. Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, Jiangsu 210029, China.